



ASX Announcement

4 December 2020

Lapse of Unlisted Share Options

Invion Limited (ASX:IVX) wishes to advise that the following unlisted share options have lapsed.

Lapsed Options	Exercise Price	Expiry Date
8,177,284	\$0.0300	12/02/2023
5,000	\$0.0175	18/11/2020

The number of options on hand following the lapse of the above options are as follows:

*ASX security code and description	*Total number of +securities on issue
IVXAT OPT @ \$0.03 Exp 12/02/2023	199,434,880
IVXAU OPT @ \$0.02 Exp 30/10/2023	2,725,761
IVXAV OPT @ \$0.0172 Exp 31/08/2024	20,443,211
IVXAAA OPT @ \$0.02 Exp 01/07/2024	15,928,570
IVXAY OPT @ \$0.0177 Exp 22/10/2024	20,443,211
IVXAW OPT @ \$0.00 Exp 31/10/2024	5,689,623
IVXAZ OPT @ \$0.0106 Exp 31/10/2024	2,725,762

Investor enquiries

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Media enquires

Brendon Lau

T: +61 409 341 613

E: brendon@vantagepointpartners.com.au

**About Invion**

Invion is a life-science company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.